TTrialPathMatch Me to Trials
← Back to trials
RecruitingAsthma

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Eligible age

10–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. The investigators are also interested in determining whether intrinsic small airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow limitation. The investigators are also interested to evaluate the role of varying doses of inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric oxide as surrogate markers of inflammation. For comparison purposes, spirometry and measurements of exhaled nitric oxide will also be obtained if possible during a naturally occurring exacerbation of asthma.

Sponsor: Gelb, Arthur F., M.D.

You may qualify if…

  • Current non-smoking (\<10 pack yr smoking history)
  • Stable, treated asthmatics
  • Age 10-80 yr
  • post 180ug albuterol by MDI: FEV 1/FVC \< 70% and FEV 1 \<80% predicted

You may not qualify if…

  • Pregnancy

Where it's recruiting

California

Lakewood

Source: ClinicalTrials.gov · NCT01225913 · last updated 2023-10-26